Viewpoint - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Viewpoint

How to Manage Effective Leadership when Change is the Only Constant

November 2, 2012

Pharmaceutical Technology

A disciplined approach to changing behavior can achieve change agility.

FDA and the Importance of Confidentiality

October 2, 2012

Pharmaceutical Technology

Recent news stories have reported that FDA scientists have been suspected of leaking confidential, commercial, and trade secret information to the media.

Technology Transfer: Protecting the True Public Interest

September 2, 2012

Pharmaceutical Technology

Ties between the biotechnology industry and university research are crucial.

Weighing Access and Affordability

September 1, 2012

Pharmaceutical Technology

Policymakers must balance fundamental issues involving access to medicines and pricing.

Enactment of FDA Reform Act Improves Drug Safety

August 2, 2012

Pharmaceutical Technology

New law provides FDA with the resources it needs to safeguard drug supply chain.

Requirements for Electronic Records Contained in 21 CFR 211

July 18, 2012

Pharmaceutical Technology

The author discusses the regulatory requirements for electronic records contained in Title 21 CFR Part 211 and how they overlap with the requirements set forth in Title 21 CFR Part 11.

Future Innovation

July 2, 2012
Pharmaceutical Technology

Presidents of leading associations offer views on the industry's future.

Biosimilar Developers Face a Reference-Product Dilemma

June 2, 2012

Pharmaceutical Technology

Does global development have to entail multiple comparability studies?

The Growing Orphan-Drug Paradigm

May 2, 2012

Pharmaceutical Technology

How niche strategies can offer mainstream potential for biopharmaceutical companies.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here